Search results
AstraZeneca’s Fasenra: Approval for asthma may initiate COPD approval
Pharmaceutical Technology via Yahoo Finance· 3 weeks agoAstraZeneca has recently announced that Fasenra has been approved for severe asthma, specifically...
AstraZeneca's (AZN) Fasenra Gets FDA Nod for Asthma in Kids
Zacks via Yahoo Finance· 1 month agoAstraZeneca AZN announced that the FDA has approved its marketed asthma drug, Fasenra...
Eosinophilic Asthma
Health via Yahoo News· 3 days agoMixMedia / Getty Images Medically reviewed by Daniel More, MDMedically reviewed by Daniel More, MD Eosinophilic asthma (also known as e-asthma or eos...
What Is Severe Asthma?
Health via Yahoo News· 2 months agoRealPeopleGroup / Getty Images Medically reviewed by Reza Samad, MD Severe asthma is the term used for asthma that is difficult to treat and control....
Pennsylvania woman stunned to be charged $50K for asthma medication. No one can explain it
USA TODAY via Yahoo News· 2 years agoYORK, Pa. — Jessica Eckard has always had asthma problems. Her father died of tuberculosis when she...
AstraZeneca's Fasenra Flunks Late-Stage Trial In Patients With Esophagus Inflammation
Benzinga via Yahoo Finance· 2 years agoAstraZeneca Plc (NASDAQ: AZN) has reported topline data from the MESSINA Phase 3 trial Fasenra...
AstraZeneca drug fails one main goal in study of chronic immune disease
Reuters via Yahoo News· 2 years agoThe condition, eosinophilic esophagitis, is characterised by inflammation and damage to the...
How Is Asthma Treated?
Health via Yahoo News· 1 year agoAsthma can be a lifelong lung condition that causes the airways to become inflamed and prone to narrowing, causing symptoms like shortness of breath and...
Pharma Stock Roundup: JNJ to Buy Shockwave Medical, Other Pipeline & Regulatory News
Zacks via Yahoo Finance· 1 month agoThis week, J&J JNJ proposed to buy medical device company Shockwave Medical SWAV for approximately...
2 Unstoppable Stocks Set to Keep Beating the Market in 2022
Motley Fool· 2 years agoLet's see why these two biotechs can continue on their march forward. Over the past year, U.K.-based...
